Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 15, Issue 2, 2000, Pages 211-217

  Mariani, Giuliano ^a   Ferdeghini, Marco ^b,d   Augeri, Carla ^a   Villa, Giuseppe ^a   Taddei, Gioconda Z ^a   Scopinaro, Giovanni ^c   Boni, Giuseppe ^d   Bodei, Lisa ^d   Rabitti, Clara ^a   Molinari, Ettore ^a   Bianchi, Romano ^d  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c GALLIERA HOSPITAL   (Italy)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

Differentiated thyroid cancer; Radioiodine scintigraphy; Radioiodine therapy; Recombinant human thyrotrophin; Thyroglobulin

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; RADIOACTIVE IODINE; RECOMBINANT HUMAN THYROTROPIN; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROTROPIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER RECURRENCE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; HYPOTHYROIDISM; MALAISE; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; SHIVERING; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROTROPIN BLOOD LEVEL; WHOLE BODY SCINTISCANNING;

EID: 0034105978     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2000.15.211     Document Type: Article

References (27)

1. Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality, 1973-1995: a report card for the U.S. Cancer 1998; 82: 1197-207.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998; 48: 6-30.
3. Black RJ, Bray F, Ferlay J, et al. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33: 1075-107.
4. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-28. [Erratum, Am J Med 1995; 98: 215.]
5. Schlumberger M, Pacini F. Thyroid Tumors. Paris: Nucléon (1999).
6. 131I whole body scans in the diagnosis of metastases from differentiated thyroid carcinoma (after thyroidectomy). Clin Endocrinol (Oxford) 1980; 50: 107-10.
7. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993; 114: 1050-8.
8. Maxon HR III, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990; 19: 685-718.
9. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot LJ. Serum thyro-globulin in the follow-up of patients treated with differentiated thyroid cancer. J Clin Endocrinol Metab 1994; 79: 98-105.
10. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma: a population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 1997; 79: 564-73.
11. 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 1997; 7: 265-71.
12. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297-306.
13. Wartofsky L, Sherman SI, Gopal J, Schlumberger M, Hay ID. Therapeutic controversy. The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab 1998; 83: 4195-203.
14. Dow KH, Ferrel BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997; 7: 613-9.
15. Thotakura MR, Desai RK, Bates LG, Cole ES, Pratt BM, Weintraub BD. Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells Endocrinology 1991; 128: 341-8.
16. Huber GK, Fong P, Concepcion ES, Davies TF. Recombinant human thyroid-stimulating hormone: initial bioactivity assessment using human fetal thyroid cells. J Clin Endocrinol Metab 1991; 72: 1328-31.
17. Braverman LE, Pratt BM, Ebner S, Longcope C. Recombinant human thyrotropin stimulates thyroid function and radioactive iodine uptake in the Rhesus monkey. J Clin Endocrinol Metab 1992; 74: 1135-9.
18. Meier CA, Braverman LE, Ebner S, Longcope C. Recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 1994; 78: 188-96.
19. 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoima and hypopituitarism. J Clin Endocrinol Metab 1996; 81: 1724-5.
20. Ramirez L, Braverman LE, White B, Emerson CH. Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects. J Clin Endocrinol Metab 1997; 82: 2836-9.
21. Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997; 337: 888-96.
22. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84: 3877-85.
23. Utiger RD. Follow-up of patients with thyroid carcinoma. N Engl J Med 1997; 337: 928-30.
24. Kiang DT, Greenberg LJ, Kennedy BJ. Tumor marker kinetics in the monitoring of breast cancer. Cancer 1990; 65: 193-199.
25. Gion M, Barioli P, Mione R, et al. Tumor markers in breast cancer follow-up: a potentially useful parameter still awaiting definitive assessment. Ann Oncol 1995; 6 (suppl 2): 31-35.
26. Gion M, Mione R, Barioli P, Dittadi R. Dynamic use of tumor markers: rational-clinical applications and pitfalls. Anticancer Res 1996; 16: 2279-2284.
27. Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid 1999; 9: 435-441.